Pfizer Inc. (PFE) SEC Filings & Earnings Calls

Non-cash intangible asset impairments of $4.3B

“Reported (4) Loss Per Share Reflects $4.3 Billion in Non-Cash Intangible Asset Impairments” · word for word

COVID product revenue revised down to ~$4B from ~$5B

“revised revenue expectation for our COVID-19 products, down to approximately $4 billion from approximately $5 billion” · word for word

Clinical trial failure risk

“$3.8 billion in impairments of IPR&D assets, associated with a Phase 3 study for sigvotatug vedotin for the second line treatment of metastatic non-squamous NSCLC, reflecting unfavorable clinical trial results”

Legal liability risk

“Certain legal matters, net (a) $842 for the three months ended June 28, 2026, compared to $422 for the three months ended June 29, 2025.”

Product discontinuation risk

“$525 million for Oxbryta (voxelotor) developed technology rights, after engaging with the FDA in July 2026 to discuss their assessment of data and analyses, and it was determined there was no viable pathway to return Oxbryta to the market in the U.S.”

Restructuring execution risk

“Restructuring charges and certain acquisition-related costs $457 for the three months ended June 28, 2026, compared to $(18) for the three months ended June 29, 2025.” · word for word

CFO transition could introduce execution risk, but guidance reaffirmation mitigates immediate concern.

“Following the disclosure of Pfizer’s Chief Financial Officer transition announcement on June 18, 2026, Pfizer today is reaffirming its fiscal year 2026 guidance.”

CFO transition risk, though stated as not related to financial results; search for permanent successor underway.

“his departure is not related to the Company’s financial or operating results or to any disagreements with the Company regarding the Company’s financial, operational, accounting or reporting policies or practices.”

Patent Expiry Cliff

“We anticipate a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years.” · word for word

IRA Drug Pricing Impact

“Negotiated prices for Ibrance and Xtandi are expected to follow in 2027, with Xeljanz effective in 2028.” · word for word

Tariff Exposure

“the U.S. Government announced Section 232 tariffs on imported patented pharmaceuticals and their ingredients, up to a 100% duty to address national security concerns regarding supply chain reliance.” · word for word

COVID Product Revenue Decline

“Comirnaty revenue -59% YoY; Paxlovid revenue -62% YoY”

Adjusted income and EPS declined 18% YoY due to higher costs or product mix.

“Adjusted Income $4,290M vs $5,237M in Q1 2025, down 18%.”

Say-on-Pay vote decline indicates governance risk

“In 2025, our Say-on-Pay vote received 54.7% support, lower than historical levels.” · word for word

Drug pricing pressure from U.S. Government agreement

“We also reached a voluntary agreement with the U.S. Government, supporting efforts to lower prescription drug costs and align prices with those in other developed countries.” · word for word

COVID-19 revenue decline

“For full-year 2025 we reported total revenues of $62.6 billion compared with $63.6 billion the previous year, reflecting a year-over-year operational decline of 2%.” · word for word

Patent Expiry and Biosimilar Competition

“the expected impact of patent expiries and generic and biosimilar competition” · word for word

COVID-19 Product Demand Decline

“demand for our COVID-19 products has and may continue to be reduced or not meet expectations” · word for word

IRA Drug Pricing Pressure

“the expected impact of the IRA Medicare Part D Redesign” · word for word

Tariff Impact on Supply Chain

“the risk and impact of tariffs on our business” · word for word

Business Development Integration Risk

“challenges integrating the businesses and operations; disruption to business or operations relationships; risks related to achieving or growing revenues for certain acquired or partnered products” · word for word

Revenue decline driven by COVID product revenue decrease; LOE expected to impact 2026 revenue by ~$1.5B.

“Full-year 2025 revenues declined 2% operationally; 2026 guidance includes ~$1.5B negative impact from LOE.”

Most-Favored-Nation drug pricing and TrumpRx expected to unfavorably impact 2026 guidance.

“Guidance reflects anticipated unfavorable impact of Most-Favored-Nation drug pricing and TrumpRx.”

Revenue decline expected in FY2026 due to COVID product decline and LOE products

“Full-year 2026 revenue guidance includes the expectation of revenues from our COVID-19 products being approximately $1.5 billion lower than what is expected in 2025 plus an expected year-over-year negative revenue impact of approximately $1.5 billion due to certain products experiencing loss of exclusivity”

Increased debt load; interest expense will rise, but maturities are staggered.

“$6.0B in new debt with coupons ranging from floating to 5.700%”

Milestone payments contingent on clinical and regulatory success; execution risk.

“CVRs tied to Phase 3 start and FDA approvals.”

Clinical Trial Failure

“Intangible asset impairment charge of $260M related to IPR&D associated with a Phase 3 study for inclacumab for the treatment of SCD, which reflects unfavorable clinical trial results.”

Acquisition Integration Risk

“Large upfront payment of $1.25B for 3SBio in-licensing deal with significant milestone payments.”

Revenue Decline from COVID Products

“Total revenues declined 6% YoY, likely driven by lower demand for Comirnaty and Paxlovid as pandemic recedes.”

COVID product revenue decline continues

“operational decrease was primarily driven by a year-over-year decline in COVID-19 product revenues largely due to lower infection rates impacting Paxlovid demand as well as a narrower vaccine recommendation for COVID-19 in the U.S.” · word for word

Tariff impact absorbed in guidance

“The company’s guidance absorbs the impact of the currently imposed tariffs from China, Canada, and Mexico.” · word for word

One-time IPR&D charge from 3SBio deal

“Includes a one-time $1.35 billion Acquired In-Process R&D charge related to the in-licensing agreement with 3SBio, Inc.” · word for word